
    
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group,
      superiority study comparing the efficacy and safety of rivaroxaban with placebo for primary
      prophylaxis of venous thromboembolism (VTE) in ambulatory adult participants, with various
      cancer types who are scheduled to initiate systemic cancer therapy. The study consists of 3
      Phases: Screening Phase (14 Days), double-blind treatment Phase (180 Days) and follow up
      Phase (30 Days). The duration of participation in the study for each participant is
      approximately 32 weeks.
    
  